Dominant Companies in India Amyloidosis Market | Competitive Landscape 2026

India Amyloidosis Market Overview

According to 6Wresearch, the India amyloidosis market is witnessing steady growth due to increasing diagnosis of rare protein misfolding disorders, rising awareness among clinicians, and expanding access to advanced diagnostic tools. Growth is further supported by improved healthcare infrastructure, growing availability of targeted therapies, and increasing clinical research activities focused on rare disease management across major hospitals in India. Rising adoption of precision medicine, better screening capabilities, and supportive government initiatives for rare disease treatment further contribute to the market's positive outlook.

Competitive Landscape

The competitive landscape in the India amyloidosis market is a mix of global pharmaceutical leaders and specialized rare disease-focused companies. These companies innovate new drugs, conduct clinical trials, and provide expanded access programs to patients across hospitals and specialty care centers.

Leading Players Operating in the India Amyloidosis Market:

1. Pfizer Inc.

A global pioneer in the managed amyloidosis segment, Pfizer provides sophisticated stabilizer solutions like Vyndakase (tafamidis) that handle complex cardiac compliance and large-scale patient management.

2. Johnson & Johnson

A major force in the global space, J&J focuses on multi-country compliance and innovative proteasome inhibitors like Darzalex for AL amyloidosis in large-scale multinational healthcare systems.

3. Eli Lilly and Company

A historic innovator in tech-led medicine, Lilly recently launched Lormalzi (donanemab) in India, marking a shift toward localized amyloid plaque-targeting therapies for neurological amyloid pathology.

4. Alnylam Pharmaceuticals

A fast-growing unicorn in the RNAi segment that provides an end-to-end gene-silencing suite, integrating specialized hardware with therapeutic performance and talent management for hereditary amyloidosis.

5. Takeda Pharmaceutical Company

Caters to the modern healthcare workforce with a patient-centric platform emphasizing transparency in clinical processing and ease of use for administrative teams managing oncology and rare diseases.

6. AstraZeneca

Combines hardware excellence with software automation, offering instant therapeutic disbursements and automated statutory payments in the rare disease segment through collaborations on TTR-degrading therapies.

7. Novartis AG

A mobile-first platform that leverages high-precision molecular data to provide high-precision clinical processing and system management for diverse cardiovascular and skin industries.

8. GlaxoSmithKline (GSK)

Part of the global tech-biotech ecosystem, this brand focuses on providing affordable, highly customizable tools integrated with broad business applications for amyloid-specific research and diagnostics.

9. Sanofi S.A.

Provides high-volume processing and workforce management solutions, supporting some of the largest private medical networks with innovative rare disease platforms and enzyme replacement therapies.

10. AbbVie Inc.

Specializes in managed systems and clinical compliance audits, delivering reliable quaternary care for complex hematologic operations and legal frameworks in the Indian market.

11. Roche

Provides high-durability hardware processing and system management solutions, supporting some of the largest diagnostic frameworks for amyloid detection in the country.

12. Ionis Pharmaceuticals

An antisense technology leader that fuses global engineering with meticulous research, empowering clinicians to embrace digital transitions through statement-making gene-silencing solutions.